Answers are grounded in this paper and cite their sources.
4D bioprinting, an emerging additive manufacturing technology, is used for creating biomedical constructs with programmed changes in shape, properties, or function over time. Unlike conventional 3D printing techniques producing static structures, 4D bioprinting integrates stimuli-responsive biomaterials to generate dynamic and adaptive constructs. This functionality is achieved by utilizing stimuli-responsive hydrogels, shape-memory polymers (SMPs), conductive polymers, magnetic-responsive systems, and natural polymer-based bioinks. Common responsive materials include poly(N-isopropylacrylamide), polyethylene glycol, polypyrrole, and polyaniline, while SMPs are PLA, PGDA, and polyurethanes; natural ones like polymer-acrylate blends of gelatin, hyaluronan, and alginate enable transformations. These materials respond to stimuli like temperature, light, pH, magnetic/electrical signals, and changes in biological environment and help in advancing drug delivery, tissue engineering, and regenerative medicine. These materials with adaptive and spatially controlled properties have eventually transformed overall patient-specific treatments. This review furnishes account on these aforementioned 4D bioprinting systems including their actuation mechanisms, printability, biocompatibility, functional performance, and translational potential. Printing resolution, manufacturing reproducibility, control over transition kinetics, interfacial mechanics, long-term biosafety, and regulatory requirements are barriers limiting their clinical translation. Hence, future progression is highly dependent upon development of highly biocompatible multi-responsive materials with improved spatiotemporal control of actuation, standardized manufacturing and characterization strategies, and robust validation.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: